LSD1/KDM1A inhibitors in clinical trials: advances and prospects.

Article Details

Citation
Copy to clipboard

Fang Y, Liao G, Yu B

LSD1/KDM1A inhibitors in clinical trials: advances and prospects.

J Hematol Oncol. 2019 Dec 4;12(1):129. doi: 10.1186/s13045-019-0811-9.

PubMed ID
31801559 [ View in PubMed
]
Abstract

Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have been reported to date, some of them such as TCP, ORY-1001, GSK-2879552, IMG-7289, INCB059872, CC-90011, and ORY-2001 currently undergo clinical assessment for cancer therapy, particularly for small lung cancer cells (SCLC) and acute myeloid leukemia (AML). This review is to provide a comprehensive overview of LSD1 inhibitors in clinical trials including molecular mechanistic studies, clinical efficacy, adverse drug reactions, and PD/PK studies and offer prospects in this field.

DrugBank Data that Cites this Article

Drugs